Ozempic and Osteoarthritis: Can a Diabetes Drug Ease Joint Pain?

For the over 500 million people worldwide living with osteoarthritis (OA), a common and often debilitating joint disease, recent hope may be on the horizon. Emerging research suggests that semaglutide, the active ingredient in medications like Ozempic and Wegovy, initially developed to treat type 2 diabetes, could potentially alleviate symptoms and even promote cartilage repair in individuals with OA. Whereas larger trials are needed, early findings are promising.

What is Osteoarthritis?

Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage, the protective tissue cushioning the ends of bones. This breakdown leads to pain, stiffness and reduced range of motion. It commonly affects the hands, knees, hips, and other joints. Currently, there is no cure for OA, and treatment focuses on managing pain and improving function.

How Semaglutide May Help

Traditionally, weight loss has been recommended to alleviate OA symptoms by reducing the load on joints. Semaglutide, known for its weight-loss effects, was initially considered a potential treatment for this reason. However, recent studies indicate that semaglutide may have a more direct impact on cartilage health, independent of weight loss.

The Science Behind the Findings

Research conducted in both mice and humans has demonstrated that semaglutide can ease OA symptoms and even thicken cartilage. A study published in Cell Metabolism on February 9, 2026, showed that semaglutide alleviates OA in a weight loss-independent manner and shifts chondrocyte metabolism from glycolysis to oxidative phosphorylation.

Further investigation, detailed in PubMed, reveals that semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, exhibits chondroprotective effects. Researchers found reduced cartilage degeneration, osteophyte formation, synovial lesions, and pain sensitivity in an OA mouse model treated with semaglutide. This effect is achieved by regulating the “GLP-1R-AMPK-PFKFB3” axis, reprogramming chondrocyte metabolism and promoting cartilage restoration.

A randomized pilot clinical study (ChiCTR2200066291) supports these findings in humans.

What the Experts Say

“Thicker cartilage suggests the tissue is being rebuilt,” says Di Chen, a physician and biologist at Shenzhen University of Advanced Technology in China. “That’s a good thing. That’s the key thing.” More cartilage translates to more cushioning, reducing bone-on-bone friction and pain.

Recent Trial Results

A study published in the New England Journal of Medicine (October 30, 2024) found that among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significant improvements.

Important Considerations and Future Research

While these findings are encouraging, it’s crucial to note that research is still in its early stages. Larger, more comprehensive clinical trials are needed to confirm these results and determine the optimal dosage, duration of treatment, and long-term effects of semaglutide for osteoarthritis. It’s also important to understand that semaglutide is not currently approved for the treatment of osteoarthritis and should only be used as prescribed by a healthcare professional for its approved indications.

Key Takeaways

• Semaglutide shows promise in alleviating osteoarthritis symptoms and potentially rebuilding cartilage.
• The benefits may be independent of weight loss.
• Research is ongoing, and larger clinical trials are needed.
• Semaglutide is not currently approved for OA treatment and should only be used as prescribed.